1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Phosphagenics soars on Phase I oxymorphone patch results

 
• By Ian Haydock

It may have been only a small Phase I trial, but investors in Phosphagenics were sufficiently convinced by positive results with a new transdermal formulation of oxymorphone to send shares in the Australian drug delivery venture surging by nearly 50% on 24 October.

It may have been only a small Phase I trial, but investors in Phosphagenics were sufficiently convinced by positive results with a new transdermal formulation of oxymorphone to send shares in the Australian drug delivery venture surging by nearly 50% on 24 October.

The Melbourne-based firm said the multi-dose study confirmed that "well above the threshold therapeutic concentrations" produced by an oral long-acting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

More from Therapy Areas

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.